PHIO News and Press, Phio Pharmaceuticals Corp. From 10/07/21

Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire MARLBOROUGH, Mass. , Oct. 7, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology compan...

Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific Conferences in October 2021 PR Newswire MARLBOROUGH, Mass. , Sept. 30, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generat...

Palm Beach, FL – September 17, 2021 – FinancialNewsMedia.com News Commentary – The ovarian cancer drugs market consists of sales of ovarian cancer drugs to treat ovarian cancer. Ovarian cancer is caused due to abnormal growth of cells in ovary. This industry...

The following slide deck was published by Phio Pharmaceuticals Corp. in conjunction with this event. For further details see: Phio Pharmaceuticals (PHIO) Presents At H. C. Wainwright 23rd Annual Global Investment Conference - Slideshow

IronNet (NYSE:IRNT) +53%. Offerpad Solutions (NYSE:OPAD) +35%. Leap Therapeutics (NASDAQ:LPTX) +33% on positive DKN-01 + tislelizumab data in gastroesophageal cancer Phio Pharmaceuticals (NASDAQ:PHIO) +20% after mPH-3861 showed durable and systemic anti-tumor immune respon...

Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4 Local treatment with PD-1 and BRD4 dual-targeting INTASYL also showed complete resolution of tumors in vivo PR Newswire MARLBOROUG...

Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th PR Newswire MARLBOROUGH, Mass. , Sept. 3, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing th...

Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021 PR Newswire MARLBOROUGH, Mass. , Aug. 31, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-...

Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update PR Newswire MARLBOROUGH, Mass. , Aug. 12, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation o...

Shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) traded today at $1.72, breaking its 52-week low. This new low was reached on below average trading volume as 166,000 shares traded hands, while the average 30-day volume is approximately 417,000 shares. Potential upside of 65.3% exists f...